Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immune (I&I) markets, including treatments for atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications [2] - The company's lead program, APG777, targets atopic dermatitis, which is identified as the largest and least penetrated market within the I&I sector [2] - Apogee aims to achieve best-in-class efficacy and dosing through its antibody programs, which are designed to address the limitations of existing therapies by utilizing advanced antibody engineering [2] Upcoming Events - Management of Apogee Therapeutics will present at the Bank of America Health Care Conference on May 13, 2025, at 1:40 p.m. P.T. / 4:40 p.m. E.T. [1] - A live and archived webcast of the presentation will be accessible on the company's website [1]
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference